Zeiss MyoCare and ZEISS MyoCare S continue to significantly slow the progression of myopia according to the latest two-year results from Asia presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) at Salt Lake City in the United States.
Additionally, the meeting heard that the latest one-year results from Europe showed ZEISS MyoCare slows myopia and reduces the risk of fast progression. ZEISS MyoCare lenses were found to be equally effective across both European and Asian children.
Additionally, data confirmed rapid adaptation to ZEISS MyoCare lenses.
Myopia Continues to Slow
In Asian children, after two years of wear, as compared to single vision lenses, ZEISS MyoCare is shown to have slowed myopia progression on average by 0.44D and 0.20 mm and ZEISS MyoCare S by 0.41D and 0.17 mm.1
In Caucasian children, after twelve months, ZEISS MyoCare slowed myopia progression on average by 0.21D and 0.14 mm, and significantly reduced the risk of fast progression.2,3 Additionally, ZEISS MyoCare lenses were seen to significantly slow myopia irrespective of past progression.4
The two ongoing multi-centre clinical trials across China and Europe aim to comprehensively evaluate the effectiveness of ZEISS MyoCare lenses to slow myopia.
References
1. Chen X, et al. (2025, May 4-8). Slowing myopia progression with cylindrical annular refractive elements (CARE)- results from a 2-year prospective multi-central trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
2. Alvarez-Peregrina, C., et al. (2025, May 4-8). Analysis of fast myopia progression and eye growth reversal in the Clinical Evaluation of MyoCare in Europe (CEME) study after 12 months wearing CARE lenses. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
3. Alvarez-Peregrina, C., et al. Clinical Evaluation of MyoCare in Europe – the CEME Study Group. Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results. Ophthalmic Physiol Opt. 2025 Apr 29. doi: 10.1111/opo.13517. Epub ahead of print. PMID: 40296784.
4. Ohlendorf, A., et al. (2025, May 4-8). Myopia progression in children: Comparison of progression one year before and during participation in a randomized controlled clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States. Aalen, 08 May 2025
